|
| 37890117 | Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group. | J Clin Oncol | 2024 |
| 37890117 | Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group. | J Clin Oncol | 2024 |
| 36585450 | Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. | Nat Cancer | 2023 |
| 37414010 | Addressing the childhood cancer crisis in sub-Saharan Africa. | Lancet Oncol | 2023 |
| 37407142 | Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial. | Lancet Haematol | 2023 |
| 36585450 | Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. | Nat Cancer | 2023 |
| 37001051 | Genomic landscape of Down syndrome-associated acute lymphoblastic leukemia. | Blood | 2023 |
| 36725118 | Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials. | Lancet Haematol | 2023 |
| 37414010 | Addressing the childhood cancer crisis in sub-Saharan Africa. | Lancet Oncol | 2023 |
| 37407142 | Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial. | Lancet Haematol | 2023 |
| 37001051 | Genomic landscape of Down syndrome-associated acute lymphoblastic leukemia. | Blood | 2023 |
| 36725118 | Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials. | Lancet Haematol | 2023 |
| 34725453 | Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children's Oncology Group Study AALL0232. | Leukemia | 2022 |
| 35887382 | Integrated DNA Copy Number and Expression Profiling Identifies IGF1R as a Prognostic Biomarker in Pediatric Osteosarcoma. | Int J Mol Sci | 2022 |
| 35690309 | Alignment of Fellowship Training with Practice Patterns for Molecular Pathologists: A Report of the Association for Molecular Pathology Training and Education Committee. | J Mol Diagn | 2022 |
| 35429647 | An Educational Assessment of Evidence Used for Variant Classification: A Report of the Association for Molecular Pathology. | J Mol Diagn | 2022 |
| 35984649 | Pharmacologic Inhibition of NT5C2 Reverses Genetic and Nongenetic Drivers of 6-MP Resistance in Acute Lymphoblastic Leukemia. | Cancer Discov | 2022 |
| 36050548 | The genomic landscape of pediatric acute lymphoblastic leukemia. | Nat Genet | 2022 |
| 34725453 | Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children's Oncology Group Study AALL0232. | Leukemia | 2022 |
| 35115686 | Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation. | Nat Genet | 2022 |
| 35429647 | An Educational Assessment of Evidence Used for Variant Classification: A Report of the Association for Molecular Pathology. | J Mol Diagn | 2022 |
| 35690309 | Alignment of Fellowship Training with Practice Patterns for Molecular Pathologists: A Report of the Association for Molecular Pathology Training and Education Committee. | J Mol Diagn | 2022 |
| 35984649 | Pharmacologic Inhibition of NT5C2 Reverses Genetic and Nongenetic Drivers of 6-MP Resistance in Acute Lymphoblastic Leukemia. | Cancer Discov | 2022 |
| 35887382 | Integrated DNA Copy Number and Expression Profiling Identifies IGF1R as a Prognostic Biomarker in Pediatric Osteosarcoma. | Int J Mol Sci | 2022 |
| 36050548 | The genomic landscape of pediatric acute lymphoblastic leukemia. | Nat Genet | 2022 |
| 35115686 | Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation. | Nat Genet | 2022 |
| 32339229 | The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study. | J Natl Cancer Inst | 2021 |
| 32339229 | The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study. | J Natl Cancer Inst | 2021 |
| 34166225 | Germline RUNX1 variation and predisposition to childhood acute lymphoblastic leukemia. | J Clin Invest | 2021 |
| 33739852 | Favorable Trisomies and <i>ETV6-RUNX1</i> Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331. | J Clin Oncol | 2021 |
| 33739795 | Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group. | Am J Surg Pathol | 2021 |
| 33888599 | Radiation-related genomic profile of papillary thyroid carcinoma after the Chernobyl accident. | Science | 2021 |
| 33823167 | Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. | Transplant Cell Ther | 2021 |
| 34319759 | Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. | J Clin Oncol | 2021 |
| 32693409 | Molecular basis of ETV6-mediated predisposition to childhood acute lymphoblastic leukemia. | Blood | 2021 |
| 33217343 | Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. | Cancer Cell | 2021 |
| 33739852 | Favorable Trisomies and <i>ETV6-RUNX1</i> Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331. | J Clin Oncol | 2021 |
| 33823167 | Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. | Transplant Cell Ther | 2021 |
| 33739795 | Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group. | Am J Surg Pathol | 2021 |
| 33888599 | Radiation-related genomic profile of papillary thyroid carcinoma after the Chernobyl accident. | Science | 2021 |
| 34319759 | Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. | J Clin Oncol | 2021 |
| 34166225 | Germline RUNX1 variation and predisposition to childhood acute lymphoblastic leukemia. | J Clin Invest | 2021 |
| 33217343 | Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. | Cancer Cell | 2021 |
| 32693409 | Molecular basis of ETV6-mediated predisposition to childhood acute lymphoblastic leukemia. | Blood | 2021 |
| 31415821 | Genotype-phenotype correlation: Inheritance and variant-type infer pathogenicity in IQSEC2 gene. | Eur J Med Genet | 2020 |
| 32191290 | Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma. | JAMA Oncol | 2020 |
| 31833174 | Homozygous variants in AMPD2 and COL11A1 lead to a complex phenotype of pontocerebellar hypoplasia type 9 and Stickler syndrome type 2. | Am J Med Genet A | 2020 |
| 31825704 | Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331. | J Clin Oncol | 2020 |
| 32160020 | Variant Interpretation for Dilated Cardiomyopathy: Refinement of the American College of Medical Genetics and Genomics/ClinGen Guidelines for the DCM Precision Medicine Study. | Circ Genom Precis Med | 2020 |
| 32100459 | Expanding the spectrum of CEP55-associated disease to viable phenotypes. | Am J Med Genet A | 2020 |